Original Article
Type II Collagen Gene Variants and Inherited Osteonecrosis of the Femoral Head
N Engl J Med 2005; 352:2294-2301June 2, 2005
- Abstract
Background
Avascular necrosis of the femoral head (ANFH) causes disability that often requires surgical intervention. Most cases of ANFH are sporadic, but we identified three families in which there was autosomal dominant inheritance of the disease and mapped the chromosomal position of the gene to 12q13.
Methods
We carried out haplotype analysis in the families, selected candidate genes from the critical interval for ANFH on 12q13, and sequenced the promoter and exonic regions of the type II collagen gene (COL2A1) from persons with inherited and sporadic forms of ANFH.
Results
We identified a G→A transition in exon 50 of COL2A1 in affected members of a four-generation family with ANFH. This transition predicts the replacement of glycine with serine at codon 1170 in a GXY repeat of type II collagen. Another pedigree was shown to harbor the same transition, but the mutant allele occurred on a different haplotype background. In a third family, a G→A transition in exon 33 of the gene, causing a glycine-to-serine change at codon 717, was detected. No mutation was found in the COL2A1 coding region in sporadic cases of ANFH.
Conclusions
All the patients with familial ANFH whom we studied carried COL2A1 mutations. In families with ANFH, haplotype and sequence analysis of the COL2A1 gene can be used to identify carriers of the mutant allele before the onset of clinical symptoms, allowing the initiation of measures that may delay progression of the disease.
Media in This Article
Figure 1
Pedigrees of the Three Families with ANFH.Figure 2
Disease Phenotypes of Autosomal Dominant ANFH.Article Activity
- Article
It has been estimated that 300,000 to 600,000 people in the United States have avascular necrosis of the femoral head (ANFH).1 Approximately 15,000 new cases of this common and disabling disorder, also called ischemic necrosis of the femoral head or osteonecrosis of the femoral head, are reported annually.2 The age at the onset of this disease is earlier than that for osteoarthritis; the diagnosis is typically made when patients are between the ages of 30 and 60 years. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. Moreover, nearly 10 percent of the 500,000 total-hip arthroplasties performed each year in the United States involve patients with ANFH.3 As a result, this disease creates a substantial socioeconomic cost as well as a burden for patients and their families.
Idiopathic osteonecrosis of the femoral head is defined as a disease that causes ischemic osteonecrosis of the femoral head without trauma or sepsis, according to the proposal put forth by the Association Research Circulation Osseous in 1993.4 In this definition, so-called steroid-induced osteonecrosis and alcohol-associated osteonecrosis are also included in this category. Although the exact pathogenesis of osteonecrosis remains unknown, it appears to involve vascular compromise, cell death, or deficient bone repair.5
We recently identified three families with idiopathic ANFH in which there was autosomal dominant inheritance of the disease and reported that the familial ANFH gene mapped to a 15-cM region between D12S1663 and D12S1632 on chromosome 12q13.6 To identify the genes associated with idiopathic osteonecrosis, we scrutinized the region by resequencing the coding and promoter regions of candidate genes.
Methods
Recruitment
The pedigrees of the three families with ANFH are shown in Figure 1Figure 1
Pedigrees of the Three Families with ANFH.. The disease was diagnosed in affected persons by clinical and radiologic criteria. The chief symptom reported by most of these patients was pain in the groin. Physical examination revealed that the patients had no other skeletal anomalies. Routine plain-film radiography of the pelvis and hip joints was used for ANFH staging, according to Ficat's classification.7 The genetic study was approved by the institutional research board of the National Health Research Institutes, Taipei, Taiwan. Written informed consent was obtained from all persons who contributed DNA and clinical information to the study. Both affected and unaffected family members were Han Chinese living in Taiwan; their ancestral origin was determined by the investigators on the basis of geography and language.Genotyping and Haplotype Analysis
Genotyping was performed with leukocyte DNA for 39 microsatellite repeat markers from chromosome 12 (Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). Reactions were performed in 96-well microtiter plates; each well contained 10 ng of DNA template, 6 μl of a polymerase-chain reaction (PCR) amplification mix (True Allele PCR Premix, Applied Biosystems), and 0.06 pmol of each primer in a final volume of 10 μl. The PCR products were analyzed on an ABI Prism 3700 DNA sequencer (Applied Biosystems). GeneScan version 3.6 and Genotyper version 3.5 (Applied Biosystems) for Windows NT were used for allele identification and size assignment. Construction of the haplotypes was performed by the GeneHunter program.8
DNA Sequence Analysis
All exons of the type 2 collagen gene (COL2A1) from core members of the families (Subjects III-7, III-8, IV-5, IV-6, and IV-7 in Family A; Subjects III-7, III-8, and IV-10 in Family B; and Subjects II-7, II-8, III-12, and III-13 in Family C) were analyzed. In addition, genomic PCR and sequencing of exons 33 and 50 were performed on DNA from all available family members, 65 persons with sporadic ANFH, and 110 controls. Leukocyte DNA was used to amplify the genomic fragments of the COL2A1 promoter as well as exons and exon–intron junctions in 39 PCR reactions. Oligonucleotide primers were designed with the use of Primer3 software9 (Table 2 of the Supplementary Appendix). PCR was initiated at 95°C for 10 minutes; this step was followed by 45 cycles of 95°C for 30 seconds, an annealing temperature for 30 seconds, and 72°C for 45 seconds. The final step took place at 72°C for 3 minutes. PCR products were treated with exonuclease I to remove excess primers. The DNA sequencing reaction was performed with the Dye Terminator kit (Applied Biosystems) with the same primers as were used in the PCR amplification, and the reaction products were separated with ABI 3700 or ABI 3730 DNA sequencers. The results were analyzed with the Phred/Phrap/Consed programs10-12 (www.phrap.org) and PolyPhred software (version 10).13
Allele-specific primer extension was used to confirm patients' heterozygous state. Amplification of exon 50 wild-type sequence was carried out with primer A (5'-AGTCAGGACACTTACAGCAG-3') plus primer B (5'-GTCCTCCTGGCCCCGTCG-3'), and amplification of exon 50 mutant sequence with primer A plus primer C (5'-GTCCTCCTGGCCCCGTCA-3'). Amplification of exon 33 wild-type sequence was carried out with primer A (5'-TCAGTGGGACTCCCAGGC-3') plus primer B (5'-GTGCCCAGGGCCTCCAGG-3'), and amplification of exon 50 mutant sequence, with primer A plus primer C (5'-GTGCCCAGGGCCTCCAGA-3').
Results
Clinical Characteristics
Three families with ANFH were recruited for the current study (Figure 1). Two of them (Families A and B) have been described previously.6 Family C was subsequently added, but only the core family members were available for the current investigation. In conjunction, 65 consecutive patients with sporadic idiopathic ANFH were enlisted during the period from July 2003 to May 2004.
Of the three families with ANFH, there were 32 living members (11 males and 21 females) in whom the disorder had been diagnosed at the time the study was initiated. Twelve members of Family A (4 male and 8 female), 11 members of Family B (6 male and 5 female), and 3 members of Family C (1 male and 2 female) were available for clinical and genetic analyses, and their profiles were compared with those of the 65 patients with sporadic ANFH (55 male and 10 female) (Table 1Table 1
Characteristics of the Patients with Familial or Sporadic ANFH.). Although the sex ratios in the two groups were quite different, we believe that this discrepancy was probably due to ascertainment bias, since we recruited more male patients than female patients from a veterans' hospital. The inherited form of ANFH was associated with a younger age at onset, bilateral hip involvement, and no apparent predisposing conditions. Approximately 85 percent of the patients with sporadic disease had one or more complicating factors, including systemic lupus erythematosus, alcohol consumption, or use of steroid medication. Consumption of alcohol was the single most important nongenetic risk factor associated with the sporadic ANFH.The clinicopathologic features of a 24-year-old patient are shown in Figure 2Figure 2
Disease Phenotypes of Autosomal Dominant ANFH.. The patient, Subject IV-5 in Family A, presented with groin pain when she was 16 years old. A hip-joint radiograph obtained when she was 21 years old revealed a Ficat's stage II lesion (Figure 2A), and a magnetic resonance image (MRI) obtained at the same time revealed apparent necrosis of the bone of the femoral head (Figure 2B). Core-decompression surgery was performed at the age of 21 years. Histopathological examination of the specimen revealed necrosis of bone and marrow tissue — findings consistent with the diagnosis of ANFH (Figure 2C).Fine Mapping of the Candidate Region
To investigate the molecular mechanisms underlying idiopathic osteonecrosis, we took a positional candidate approach to isolate the mutated gene in the families with autosomal dominant ANFH. We first conducted haplotype analysis in two families in which linkage to chromosome 12 had been found and further defined the candidate region for ANFH. In Family A, recombination events were evident in Subjects III-20 and IV-2, and the breakpoints helped to narrow the ANFH-critical region to an 8.2-cM interval between D12S1301 and D12S339 (Figure 1A). We inferred that this genomic segment might harbor the gene for the disease in this family. The affected members of Family B shared, within the family, a haplotype in the ANFH-critical region. However, this disease-associated haplotype, defined by markers between D12S1663 and D12S2196, differed from that of the affected members of Family A. We did not carry out haplotype analysis of the third family with ANFH (Family C).
COL2A1 Gene Mutations in Familial ANFH
Using Genome Browser (National Center for Biotechnology Information, build 33, April 2003), we identified 21 known genes and 25 predicted genes in the 5.13-Mb critical region between D12S1301 and D12S339. Genes with functions related to bone and cartilage physiology were considered candidates for autosomal dominant ANFH. Among them, COL2A1 was mapped to 12q13.11–q13.2; it encodes type II collagen, a major structural protein in the extracellular matrix of cartilage. Since type II collagen provides mechanical strength in the cartilage, a mutation in the COL2A1 gene might be the cause of the hip-joint disorder in the affected families.
We applied a resequencing strategy to investigate this possibility and to uncover any genetic alterations in COL2A1 that may be associated with ANFH. A 3665G→A transition (GenBank accession number NM_001844) that caused a change from glycine to serine at amino acid position 1170 (GenBank accession number NP_001835) was identified in all 12 available patients from Family A and all 11 available patients from Family B (Figure 3AFigure 3
COL2A1 Mutations in Families with ANFH.). In all the available patients from Family C, a 2306G→A transition (GenBank accession number NM_001844) was identified (Figure 3B); this transition resulted in a change from glycine to serine in the GXY repeat at amino acid position 717 (GenBank accession number NP_001835) of the predicted protein. The two mutations were not found in either the 110 controls or the 65 persons with sporadic ANFH whom we analyzed. To confirm the heterozygous state of the sequenced mutations, we conducted additional DNA-based diagnostic tests by means of allele-specific primer extension (Figure 3C) and heteroduplex analysis with the use of single-strand conformational polymorphism and denaturing high-performance liquid chromatography techniques (Fig. 1 and 2 of the Supplementary Appendix). All the assay results are consistent with the conclusion that the patients have a mutant allele as well as a wild-type allele.Discussion
In this study, we succeeded in using a positional candidate approach to identify the COL2A1 gene from the chromosome 12q13 region as the gene that is mutated in the inherited form of ANFH. Three points lend support to the idea that the identified mutations in the COL2A1 gene might be the cause of the disease in the three families we examined. First, the COL2A1 gene transitions segregated with the disease in these families. Second, the variant sequence did not occur in 220 chromosomes of 110 controls examined. Third, the amino acid change falls at a critical position in the GXY triple-helix repeat of the encoded collagen molecule. Thus, we conclude that the structural alteration in the GXY repeat domain of type II collagen contributes to the pathogenesis of autosomal dominant ANFH.
The clinical features of the three multiplex families are similar to those of the sporadic cases of ANFH seen more commonly in orthopedic practice. Except for the hip joints, the affected persons were otherwise normal, with average height and normal spine development (Figure 3 of the Supplementary Appendix). Moreover, they had no anomalies of the ocular or auditory system. Notably, the COL2A1 gene transitions found in the three families with ANFH result in a glycine-to-serine amino acid change in the GXY repeat of the collagen (Figure 3D). We speculate that, unlike other type II collagenopathies (which are caused by deletion of the gene, truncation of the protein, or substitution with a bulky amino acid),14 the COL2A1 transitions in familial ANFH might have a milder effect on the structure and function of the protein.
A glycine-to-serine substitution has been reported in several inherited skeletal disorders involving type II collagen, including achondrogenesis or hypochondrogenesis,15-20 spondyloepiphyseal dysplasia,21-25 and osteoarthritis26 (Table 3 of the Supplementary Appendix). It is intriguing that the transitions reported here are distinct from other COL2A1 mutations and that they result in glycine-to-serine alterations at different positions in the triple-helix domain. Moreover, it is apparent that glycine-to-serine amino acid substitutions in this domain can give rise to diseases with different clinical presentations and varying degrees of severity. It remains to be determined how glycine-to-serine alterations at different positions could affect the post-translational processing of type II collagen and, consequently, contribute to variable pathophysiological and clinical manifestations. Perhaps, depending on its location in the GXY repeat domain, a specific type of glycine-to-serine substitution might change the fibril structure and interfere with the molecular interactions with other extracellular matrix constituents, such as proteoglycans. In addition, the expression level of the mutant allele relative to the wild-type allele in specific tissues could also have an effect on triple-helix composition and, consequently, clinical severity.
DNA-sequence analysis of the COL2A1 gene in members of Family A allowed us to identify persons at risk for ANFH. Among 19 persons who had no symptoms at the initial medical examination, 16 had G/G homozygosity at nucleotide position 3665, whereas 3 (Subjects III-15, III-22, and IV-9) had a G→A transition. These three subjects also carried the same haplotype in the critical interval between D12S1301 and D12S339 as the patients with ANFH. Groin pain subsequently developed in two of the three subjects (III-15 and III-22, both adults), and a recent radiograph of the hip in Subject III-22 revealed late-stage ANFH (Ficat's stage IV) (Figure 2D). We conclude that although there is individual variability in the age at onset and in tolerance of the symptoms of the disease, the results of DNA testing coincide with the clinical diagnosis. Moreover, COL2A1 haplotype and sequence analysis can potentially allow presymptomatic diagnostic testing to be offered to members of families with ANFH.
The third subject (IV-9), currently six years old, does not have the disease, and the most recent radiograph showed normal development of the hips and spine (Figure 3C of the Supplementary Appendix). As we found in our previous genetic study of two ANFH kindreds,6 the development of hip-joint problems in carriers of the COL2A1 mutant allele did not occur until adulthood. Thus, the identification of presymptomatic carriers of ANFH (Subjects III-15, III-22, and IV-9 in Family A and Subjects IV-3, V-1, V-2, V-4, V-5, and V-6 in Family B) provides an opportunity to study the natural history of the disease. Given the genetic basis of the disease, it is now possible to apply radiographic and metabolic indexes, such as measurement of the concentration of collagen fragment in the blood or urine,27 to monitor the progression of the disease.
The discovery of COL2A1 as the “causative” disease gene underlying inherited ANFH is unexpected. As its name implies, ANFH is attributed to a compromised vascular supply, but type II collagen is a marker for chondrocytes. Furthermore, mutation of the COL2A1 gene is known to be the cause of congenital disorders of the skeletal system. The results of the current study, however, suggest that defective cartilage function or abnormal bone homeostasis due to COL2A1 mutations could also play a role in the pathogenesis of osteonecrosis of the femoral head.
Several strategies have been tested for the preservation of the femoral head in patients with osteonecrosis, including surgical procedures28 and medication with osteoinductive or angiogenic agents29 to enhance bone formation and repair.30 The goal of these approaches is either to reduce the intraosseous pressure in the femoral head, and thereby restore normal vascular flow, or to enhance regional vascularization. It is known that core decompression for osteonecrosis of the hip has an effect on the natural history and clinical progression of the disease when necrotic involvement of the femoral head is limited.28 Therefore, molecular analysis of the COL2A1 gene can be used in families with ANFH to provide an indication for intervention when there is an early sign of osteonecrosis.
Supported by a grant from the National Research Program for Genomic Medicine of the National Science Council (to Dr. W.-M. Chen) and intramural grants from the National Health Research Institutes (to Dr. Tsai) and Taipei Veterans General Hospital (to Dr. W.-M. Chen).
Drs. Liu and W.-M. Chen contributed equally to this work.
We are indebted to Professor K.D. Wuu for enthusiastic support of the collaborative research on ANFH; to Drs. I-Cheng Ho, Shih-Tzu Tsai, Ken N. Kuo, and Shih-Chieh Hung and Mr. Stephen Chen for critical reading and discussion of the manuscript; to members of the families with ANFH for donating blood samples for this study; and to the National Clinical Core for Genomic Medicine at the Institute of Biomedical Sciences of Academia Sinica for collecting and handling the samples.
Source Information
From the Institute of Genetics and Genome Research Center (Y.-F. Liu, J.-S.S., K.-J.H., S.-F.T.) and the Department of Surgery (W.-M.C., P.-Y.L.) and Faculty of Medicine (M.-W.L.), School of Medicine, National Yang-Ming University; the Departments of Orthopedics and Traumatology (W.-M.C.), Medical Research and Education (M.-W.L., K.-J.H.), and Ophthalmology (P.-Y.L.), Taipei Veterans General Hospital; the Division of Molecular and Genomic Medicine, National Health Research Institutes (Y.-F. Lin, L.-H.L., Y.-H.C., Y.-S.J., S.-F.H., S.-F.T.); the Division of Orthopedics and Traumatology, Taipei Municipal Chung-Hsing Hospital (R.-C.Y.); the Department of Pathology, Chang Gung Memorial Hospital (S.-F.H.); and the Institute of Biomedical Sciences, Academia Sinica (C.S.J.F., H.-W.H., Y.-T.C.) — all in Taipei, Taiwan.
Address reprint requests to Dr. Tsai at the Division of Molecular and Genomic Medicine, National Health Research Institutes, 35 Keyan Rd., Zhunan Town, Miaoli County 350, Taiwan, or at petsai@nhri.org.tw.
- References
References
1
Lieberman JR ,Berry DJ ,Mont MA , et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect 2003;52:337-355
Medline2
Mont MA ,Hungerford DS . Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995;77:459-474
Web of Science | Medline3
Urbaniak JR ,Coogan PG ,Gunneson EB ,Nunley JA . Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting: a long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am 1995;77:681-694
Web of Science | Medline4
Gardeniers JWM . ARCO (Association Research Circulation Osseous): report of the Committee of Staging and Nomenclature. ARCO News 1993;5:79-825
Assouline-Dayan Y ,Chang C ,Greenspan A ,Shoenfeld Y ,Gershwin ME . Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94-124
CrossRef | Web of Science | Medline6
Chen WM ,Liu YF ,Lin MW , et al. Autosomal dominant avascular necrosis of femoral head in two Taiwanese pedigrees and linkage to chromosome 12q13. Am J Hum Genet 2004;75:310-317
CrossRef | Web of Science | Medline7
Ficat RP . Idiopathic bone necrosis of the femoral head: early diagnosis and treatment. J Bone Joint Surg Br 1985;67:3-9
Web of Science | Medline8
Kruglyak L ,Daly MJ ,Reeve-Daly MP ,Lander ES . Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347-1363
Web of Science | Medline9
Rozen S ,Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-386
Medline10
Ewing B ,Hillier L ,Wendl MC ,Green P . Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175-185
Web of Science | Medline11
Ewing B ,Green P . Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998;8:186-194
Web of Science | Medline12
Gordon D ,Abajian C ,Green P . Consed: a graphical tool for sequence finishing. Genome Res 1998;8:195-202
Web of Science | Medline13
Nickerson DA ,Tobe VO ,Taylor SL . PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997;25:2745-2751
CrossRef | Web of Science | Medline14
Kuivaniemi H ,Tromp G ,Prockop DJ . Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Hum Mutat 1997;9:300-315
CrossRef | Web of Science | Medline15
Mortier GR ,Weis M ,Nuytinck L , et al. Report of five novel and one recurrent COL2A1 mutations with analysis of genotype-phenotype correlation in patients with a lethal type II collagen disorder. J Med Genet 2000;37:263-271
CrossRef | Web of Science | Medline16
Horton WA ,Machado MA ,Ellard J , et al. Characterization of a type II collagen gene (COL2A1) mutation identified in cultured chondrocytes from human hypochondrogenesis. Proc Natl Acad Sci U S A 1992;89:4583-4587
CrossRef | Web of Science | Medline17
Chan D ,Cole WG ,Chow CW ,Mundlos S ,Bateman JF . A COL2A1 mutation in achondrogenesis type II results in the replacement of type II collagen by type I and III collagens in cartilage. J Biol Chem 1995;270:1747-1753
CrossRef | Web of Science | Medline18
Korkko J ,Cohn DH ,Ala-Kokko L ,Krakow D ,Prockop DJ . Widely distributed mutations in the COL2A1 gene produce achondrogenesis type II/hypochondrogenesis. Am J Med Genet 2000;92:95-100
CrossRef | Web of Science | Medline19
Bonaventure J ,Cohen-Solal L ,Ritvaniemi P , et al. Substitution of aspartic acid for glycine at position 310 in type II collagen produces achondrogenesis II, and substitution of serine at position 805 produces hypochondrogenesis: analysis of genotype-phenotype relationships. Biochem J 1995;307:823-830
Web of Science | Medline20
Vissing H ,D'Alessio M ,Lee B ,Ramirez F ,Godfrey M ,Hollister DW . Glycine to serine substitution in the triple helical domain of pro-alpha 1 (II) collagen results in a lethal perinatal form of short-limbed dwarfism. J Biol Chem 1989;264:18265-18267
Web of Science | Medline21
Ritvaniemi P ,Sokolov BP ,Williams CJ , et al. A single base mutation in the type II procollagen gene (COL2A1) that converts glycine alpha 1-247 to serine in a family with late-onset spondyloepiphyseal dysplasia. Hum Mutat 1994;3:261-267
CrossRef | Web of Science | Medline22
Winterpacht A ,Hilbert M ,Schwarze U ,Mundlos S ,Spranger J ,Zabel B . Autosomal dominant spondylarthropathy due to a type II procollagen gene (COL2A1) point mutation. Hum Mutat 1994;4:257-262
CrossRef | Web of Science | Medline23
Winterpacht A ,Hilbert K ,Schwarze U ,Zabel B . Non-radioactive multiplex-SSCP analysis: detection of a new type II procollagen gene (COL2A1) mutation. Hum Genet 1995;95:437-439
CrossRef | Web of Science | Medline24
Chan D ,Cole WG . Low basal transcription of genes for tissue-specific collagens by fibroblasts and lymphoblastoid cells: application to the characterization of a glycine 997 to serine substitution in alpha 1(II) collagen chains of a patient with spondyloepiphyseal dysplasia. J Biol Chem 1991;266:12487-12494
Web of Science | Medline25
Cole WG ,Hall RK ,Rogers JG . The clinical features of spondyloepiphyseal dysplasia congenita resulting from the substitution of glycine 997 by serine in the alpha 1(II) chain of type II collagen. J Med Genet 1993;30:27-35
CrossRef | Web of Science | Medline26
Williams CJ ,Rock M ,Considine E , et al. Three new point mutations in type II procollagen (COL2A1) and identification of a fourth family with the COL2A1 Arg519→Cys base substitution using conformation sensitive gel electrophoresis. Hum Mol Genet 1995;4:309-312
CrossRef | Web of Science | Medline27
Christgau S ,Garnero P ,Fledelius C , et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-215
CrossRef | Web of Science | Medline28
Lieberman JR . Core decompression for osteonecrosis of the hip. Clin Orthop 2004;418:29-33
CrossRef | Web of Science | Medline29
Mont MA ,Jones LC ,Einhorn TA ,Hungerford DS ,Reddi AH . Osteonecrosis of the femoral head: potential treatment with growth and differentiation factors. Clin Orthop 1998;355:Suppl:S314-S335
Web of Science | Medline30
Agarwala S ,Sule A ,Pai BU ,Joshi VR . Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002;41:346-347
CrossRef | Web of Science | Medline
- Citing Articles (39)
Citing Articles
1
Ajay Vora. (2011) Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. British Journal of Haematology 155:5, 549-560
CrossRef2
Peijian Tong, Chengliang Wu, Hongting Jin, Qiang Mao, Nanze Yu, Jonathan D. Holz, Letian Shan, Hui Liu, Luwei Xiao. (2011) Gene Expression Profile of Steroid-induced Necrosis of Femoral Head of Rats. Calcified Tissue International 89:4, 271-284
CrossRef3
Wei-Ming Chen. (2011) Osteonecrosis of the femoral head: Surgical perspective. Formosan Journal of Surgery 44:4, 131-135
CrossRef4
Peter Kannu, D.D. O'Rielly, J.C. Hyland, L. Ala Kokko. (2011) Avascular necrosis of the femoral head due to a novel C propeptide mutation in COL2A1. American Journal of Medical Genetics Part A 155:7, 1759-1762
CrossRef5
Peter Kannu, Melita Irving, Salim Aftimos, Ravi Savarirayan. (2011) Two Novel COL2A1 Mutations Associated with a Legg-Calvé-Perthes Disease-like Presentation. Clinical Orthopaedics and Related Research® 469:6, 1785-1790
CrossRef6
Anastasios V. Korompilias, Alexandros E. Beris, Marios G. Lykissas, Ioannis P. Kostas-Agnantis, Panayiotis N. Soucacos. (2011) Femoral head osteonecrosis: Why choose free vascularized fibula grafting. Microsurgery 31:3, 223-228
CrossRef7
Peter Kannu, John Bateman, Ravi Savarirayan. (2011) Clinical phenotypes associated with type II collagen mutations. Journal of Paediatrics and Child Healthno-no
CrossRef8
Jung-Taek Hwang, Seung-Ho Baik, Jin-Soo Choi, Kweon-Haeng Lee, Seung-Koo Rhee. (2011) Genetic Traits of Avascular Necrosis of the Femoral Head Analyzed by Array Comparative Genomic Hybridization and Real-Time Polymerase Chain Reaction. Orthopedics
CrossRef9
George C. Babis, Vasileios Sakellariou, Javad Parvizi, Panayiotis Soucacos. (2011) Osteonecrosis of the Femoral Head. Orthopedics 34:1, 39-48
CrossRef10
Peiqiang Su, Liangming Zhang, Yan Peng, Anjing Liang, Kaili Du, Dongsheng Huang. (2010) A histological and ultrastructural study of femoral head cartilage in a new type II collagenopathy. International Orthopaedics 34:8, 1333-1339
CrossRef11
You-Shui Gao, Chang-Qing Zhang. (2010) Cytotherapy of osteonecrosis of the femoral head: a mini review. International Orthopaedics 34:6, 779-782
CrossRef12
Pengde Kang, Hong Gao, Fuxing Pei, Bin Shen, Jing Yang, Zongke Zhou. (2010) Effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. International Journal of Experimental Pathology 91:3, 235-243
CrossRef13
Valérie Gangji, Jean-Philippe Hauzeur. (2010) Treating osteonecrosis with autologous bone marrow cells. Skeletal Radiology 39:3, 209-211
CrossRef14
Jih-Yang Ko, Feng-Sheng Wang, Ching-Jen Wang, To Wong, Wen-Yi Chou, Shin-Ling Tseng. (2010) Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 46:3, 584-591
CrossRef15
Huarong Zhang, Lei Zhang, Jun Wang, Yingying Ma, Jing Zhang, Fan Mo, Weiyi Zhang, Shigui Yan, Guojing Yang, Biaoyang Lin. (2009) Proteomic Analysis of Bone Tissues of Patients with Osteonecrosis of the Femoral Head. OMICS: A Journal of Integrative Biology 13:6, 453-466
CrossRef16
Jean-Cyr Yombi, Bernard Vandercam, Dunja Wilmes, Jean-Emile Dubuc, Anne Vincent, Pierre-Louis Docquier. (2009) Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review. Clinical Rheumatology 28:7, 815-823
CrossRef17
Mohammad Amin Kerachian, Chantal Séguin, Edward J. Harvey. (2009) Glucocorticoids in osteonecrosis of the femoral head: A new understanding of the mechanisms of action. The Journal of Steroid Biochemistry and Molecular Biology 114:3-5, 121-128
CrossRef18
Michael G. Zywiel, Mike S. McGrath, Thorsten M. Seyler, David R. Marker, Peter M. Bonutti, Michael A. Mont. (2009) Osteonecrosis of the Knee: A Review of Three Disorders. Orthopedic Clinics of North America 40:2, 193-211
CrossRef19
Peter Kannu, John F. Bateman, Daniele Belluoccio, Amanda J. Fosang, Ravi Savarirayan. (2009) Employing molecular genetics of chondrodysplasias to inform the study of osteoarthritis. Arthritis & Rheumatism 60:2, 325-334
CrossRef20
S.-C. Mu, H.-C. Liu, J.-Y. Wu, M.-T. M. Lee, H.-P. Chuang, L.-K. Chen, Y.-T. Chen. (2009) A large kindred of early-onset osteoarthritis of the knee and hip: excluding the link to COL2A1 gene. Rheumatology 48:4, 371-374
CrossRef21
Ola Wiig. (2009) Perthes' disease in Norway. Acta Orthopaedica 80:s333, 1-44
CrossRef22
Hideto Kameda, Koichi Amano, Hayato Nagasawa, Hiroe Ogawa, Naoya Sekiguchi, Hirofumi Takei, Katsuya Suzuki, Tsutomu Takeuchi. (2009) Notable Difference between the Development of Vertebral Fracture and Osteonecrosis of the Femoral Head in Patients Treated with High-dose Glucocorticoids for Systemic Rheumatic Diseases. Internal Medicine 48:22, 1931-1938
CrossRef23
Ying-Xia Cui, Xin-Yi Xia, Ying Bu, Guo-Hua Zhou, Bin Yang, Hong-Yong Lu, Yi-Chao Shi, Lian-Jun Pan, Yu-Feng Huang, Xiao-Jun Li. (2008) Rapid Molecular Prenatal Diagnosis of Spondyloepiphyseal Dysplasia Congenita by PCR-SSP Assay. Genetic Testing 12:4, 533-536
CrossRef24
Régis Levasseur. (2008) Mechanisms of osteonecrosis. Joint Bone Spine 75:6, 639-642
CrossRef25
T.-H. Kim, J.M. Hong, B. Oh, Y.S. Cho, J.-Y. Lee, H.-L. Kim, E.-S. Shin, J.-E. Lee, E.K. Park, S.-Y. Kim. (2008) Genetic association study of polymorphisms in the catalase gene with the risk of osteonecrosis of the femoral head in the Korean population. Osteoarthritis and Cartilage 16:9, 1060-1066
CrossRef26
Re-Wen Wu, Feng-Sheng Wang, Jih-Yang Ko, Ching-Jen Wang, Shin-Long Wu. (2008) Comparative serum proteome expression of osteonecrosis of the femoral head in adults. Bone 43:3, 561-566
CrossRef27
Peiqiang Su, Ru Li, Shangli Liu, Yan Zhou, Xinguang Wang, Nilesh Patil, Christopher S. Mow, Justin C. Mason, Dongsheng Huang, Yiming Wang. (2008) Age at onset–dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calvé-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation ofCOL2A1. Arthritis & Rheumatism 58:6, 1701-1706
CrossRef28
T.-H. Kim, J.M. Hong, J.-Y. Lee, B. Oh, E.K. Park, C.-K. Lee, S.-C. Bae, S.-Y. Kim. (2008) Promoter polymorphisms of the vascular endothelial growth factor gene is associated with an osteonecrosis of the femoral head in the Korean population. Osteoarthritis and Cartilage 16:3, 287-291
CrossRef29
Ronald D. Barr, Alessandra Sala. (2008) Osteonecrosis in children and adolescents with cancer. Pediatric Blood & Cancer 50:S2, 483-485
CrossRef30
Georgios Hadjigeorgiou, Efthimios Dardiotis, Maria Dardioti, Apostolos Karantanas, Apostolos Dimitroulias, Konstantinos Malizos. (2007) Genetic association studies in osteonecrosis of the femoral head: mini review of the literature. Skeletal Radiology 37:1, 1-7
CrossRef31
Xinyi Xia, Yingxia Cui, Yufeng Huang, Lianjun Pan, Yongming Wu, Pingping Zhang, Baofang Jin. (2007) A first familial G504S mutation of COL2A1 gene results in distinctive spondyloepiphyseal dysplasia congenita. Clinica Chimica Acta 382:1-2, 148-150
CrossRef32
Alan L. Buchman. (2007) Metabolic Bone Disease and Inflammatory Bowel Disease. The American Journal of Gastroenterology 102:s1, S49-S55
CrossRef33
Yoshinari Miyamoto, Tatsuo Matsuda, Hiroshi Kitoh, Nobuhiko Haga, Hirofumi Ohashi, Gen Nishimura, Shiro Ikegawa. (2007) A recurrent mutation in type II collagen gene causes Legg-Calvé-Perthes disease in a Japanese family. Human Genetics 121:5, 625-629
CrossRef34
Alessandra Sala, Leonard A. Mattano, Ronald D. Barr. (2007) Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy. European Journal of Cancer 43:4, 683-689
CrossRef35
M. Ángeles Martínez-Ferrer, Pilar Peris, Núria Guañabens. (2007) Osteonecrosis. What Is New?. Reumatolog ía Cl ínica (English Edition) 3:2, 78-84
CrossRef36
Pierre Lafforgue. (2006) Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 73:5, 500-507
CrossRef37
Gary R. Lichtenstein, Maria T. Abreu, Russell Cohen, William Tremaine. (2006) American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease. Gastroenterology 130:3, 940-987
CrossRef38
E. Seeman. (2005) Clinical and Basic Research Papers - June 2005 Selections. International Bone and Mineral Society Knowledge Environment 2:7, 1-5
CrossRef39
Prockop, Darwin J., . (2005) Type II Collagen and Avascular Necrosis of the Femoral Head. New England Journal of Medicine 352:22, 2268-2270
Full Text
